Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

被引：10

作者：

Sanchez, Larysa ^{[1
]}

Schinke, Carolina ^{[2
]}

Krishnan, Amrita ^{[3
]}

Berdeja, Jesus G. ^{[4
]}

de Donk, Niels W. C. J. van ^{[5
]}

Mateos, Maria Victoria ^{[6
]}

Chari, Ajai ^{[7
]}

Parekh, Samir ^{[8
]}

Mouhieddine, Tarek H. ^{[9
]}

Jagannath, Sundar ^{[10
]}

Bahlis, Nizar J. ^{[11
]}

Touzeau, Cyrille ^{[12
]}

Oriol, Albert ^{[13
,14
]}

San-Miguel, Jesus ^{[15
]}

Otero, Paula Rodriguez ^{[16
]}

Minnema, Monique C. ^{[17
]}

Campagna, Michela ^{[18
]}

Masterson, Tara J. ^{[19
]}

Hilder, Brandi W. ^{[19
]}

Tolbert, Jaszianne ^{[19
]}

Renaud, Thomas ^{[20
]}

Gray, Kathleen ^{[21
]}

Smit, Damiette ^{[22
]}

Heuck, Christoph ^{[19
]}

Rasche, Leo ^{[23
]}

机构：

[1] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[2] Univ Arkansas Med Sci, Myeloma Ctr, Little Rock, AR USA

[3] City Hope Natl Med Ctr, Judy & Bernard Briskin Ctr Multiple Myeloma Res, Irvine, CA USA

[4] Sarah Cannon Res Inst, Nashville, TN USA

[5] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands

[6] Univ Hosp Salamanca IBSAL CIC CIBERONC, Salamanca, Spain

[7] Mt Sinai Sch Med, New York, NY USA

[8] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[9] Icahn Sch Med Mt Sinai, Dept Med Hematol & Med Oncol, Tisch Canc Inst, New York, NY USA

[10] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[11] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[12] Ctr Hosp Univ Nantes, Nantes, France

[13] Hosp Germans Trias I Pujol, Inst Catala Oncol, Barcelona, Spain

[14] Hosp Germans Trias I Pujol, Inst Josep Carreras, Barcelona, Spain

[15] Clin Univ Navarra, Inst Invest Sanitaria Navarra, Ctr Invest Med Aplicada, Ctr Invest Biomed Red Canc CIBERONC, Pamplona, Spain

[16] Clin Univ Navarra, Pamplona, Spain

[17] Univ Med Ctr Utrecht, Utrecht, Netherlands

[18] Janssen Res & Dev, Madrid, Spain

[19] Janssen Res & Dev, Spring House, PA USA

[20] Janssen Res & Dev, Raritan, NJ USA

[21] Janssen Sci Affairs, Horsham, PA USA

[22] Janssen Biol Europe, Leiden, Netherlands

[23] Univ Hosp Wurzburg, Wurzburg, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182330

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：7

共 50 条

[21] Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
Richardson, Paul G.
Chanan-Khan, Asher A.
Lonial, Sagar
Krishnan, Amrita Y.
Carroll, Michael P.
Alsina, Melissa
Albitar, Maher
Berman, David
Messina, Marianne
Anderson, Kenneth C.
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (06) : 729 - 740
[22] A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
Watanabe, Takashi
Tobinai, Kensei
Matsumoto, Morio
Suzuki, Kenshi
Sunami, Kazutaka
Ishida, Tadao
Ando, Kiyoshi
Chou, Takaaki
Ozaki, Shuji
Taniwaki, Masafumi
Uike, Naokuni
Shibayama, Hirohiko
Hatake, Kiyohiko
Izutsu, Koji
Ishikawa, Takayuki
Shumiya, Yoshihisa
Kashihara, Tomohisa
Iida, Shinsuke
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (05) : 745 - 756
[23] Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs)
Mouhieddine, Tarek H.
Van Oekelen, Oliver
Pan, Darren
Agte, Sarita
Aleman, Adolfo
Melnekoff, David T.
Lancman, Guido
Thibaud, Santiago
Sanchez, Larysa
Richard, Shambavi
Richter, Joshua
Cho, Hearn Jay
Chari, Ajai
Jagannath, Sundar
Parekh, Samir
BLOOD, 2021, 138
[24] Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Krishnan, Amrita Y.
Minnema, Monique C.
Berdeja, Jesus G.
Oriol, Albert
van de Donk, Niels W. C. J.
Rodriguez-Otero, Paula
Askari, Elham
Mateos, Maria-Victoria
Costa, Luciano J.
Verona, Raluca I.
Ma, Xuewen
Girgis, Suzette
Yang, Shiyi
Hilder, Brandi W.
Russell, Jeffery
Goldberg, Jenna D.
Chari, Ajai
BLOOD, 2021, 138
[25] Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1.
Rodriguez-Otero, Paula
Schinke, Carolina D.
Chari, Ajai
Lipe, Brea
Lavi, Noa
Rasche, Leo
Vishwamitra, Deeksha
Skerget, Sheri
Verona, Raluca
Ma, Xuewen
Khedkar, Sheetal
Hilder, Brandi
Masterson, Tara J.
Campagna, Michela
Renaud, Thomas
Tolbert, Jaszianne A.
Heuck, Christoph
Smit, Marie-Anne Damiette
van de Donk, Niels W. C. J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[26] Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study
Iida, Shinsuke
Watanabe, Takashi
Matsumoto, Morio
Suzuki, Kenshi
Sunami, Kazutaka
Ishida, Tadao
Ando, Kiyoshi
Chou, Takaaki
Ozaki, Shuji
Taniwaki, Masafumi
Uike, Naokuni
Shibayama, Hirohiko
Hatake, Kiyohiko
Izutsu, Koji
Ishikawa, Takayuki
Shumiya, Yoshihisa
Tobinai, Kensei
CANCER SCIENCE, 2019, 110 (09) : 2924 - 2932
[27] Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study
Lesokhin, Alexander
LeBlanc, Richard
Dimopoulos, Meletios A.
Capra, Marcelo
Carlo-Stella, Carmelo
Karlin, Lionel
Castilloux, Jean-Francois
Forsberg, Peter
Parmar, Gurdeep
Tosikyan, Axel
Pour, Ludek
Ribrag, Vincent
Ribolla, Rossella
Abdallah, Al-Ola
Le Roux, Nadia
Dong, Liyan
van de Velde, Helgi
Mayrargue, Laurent
Lepine, Lucie
Mace, Sandrine
Moreau, Philippe
CANCER MEDICINE, 2023, 12 (09): : 10254 - 10266
[28] TANESPIMYCIN AND BORTEZOMIB IN PATIENTS WITH RELAPSED AND RELAPSED AND REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS OF A PHASE 1/2 STUDY
Richardson, P. G.
Chanan-Khan, A.
Lonial, S.
Krishnan, A.
Carroll, M.
Alsina, M.
Albitar, M.
Berman, D.
Szatrowski, T.
Kaplita, S.
Anderson, K. C.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 152 - 153
[29] A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma
Cornell, Robert Frank
Baz, Rachid
Richter, Joshua R.
Rossi, Adriana
Vogl, Dan T.
Chen, Christine
Shustik, Chaim
Alvarez, Mariano J.
Shen, Yao
Unger, T. J.
Ben-Shahar, Osnat
Wang, Hongwei
Baloglu, Erkan
Senapedis, William
Ma, Xiwen
Landesman, Yosef
Bai, Xiang
Bader, Justin
Xu, Hongmei
Marshall, Tracey
Chang, Hua
Walker, Christopher J.
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
Hofmeister, Craig C.
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (02) : E54 - E58
[30] Novel Therapies for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: A Review of Clinical Trials
Iftikhar, Ahmad
Ahmad, Muhammad
Pachika, Pranali
Razzaq, Faryal
Ali, Muhammad Ashar Ashar
Farrukh, Hizra
Latif, Azka
Anwer, Faiz
BLOOD, 2020, 136

← 1 2 3 4 5 →